EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE
Objective: to study the prognostic significance of the expression of cancer-testis (CT) genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in patients with multiple myeloma (MM) and their influence on overall survival and relapse rate. To determine their effect on suсh clini...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2018-07-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241185994932224 |
|---|---|
| author | A. A. Solodovnik H. S. Mkrtchyan V. A. Misyurin V. V. Tikhonova Yu. P. Finashutina N. N. Kasatkina O. N. Solopova O. M. Votyakova O. Yu. Yakimovich O. M. Volodina M. Yu. Kichigina E. G. Medvedovskaya A. S. Antipova I. Z. Zavodnova A. A. Semenova G. R. Arakelyan Yu. E. Ryabukhina O. A. Kolomeytsev A. D. Shirin E. A. Osmanov A. V. Misyurin |
| author_facet | A. A. Solodovnik H. S. Mkrtchyan V. A. Misyurin V. V. Tikhonova Yu. P. Finashutina N. N. Kasatkina O. N. Solopova O. M. Votyakova O. Yu. Yakimovich O. M. Volodina M. Yu. Kichigina E. G. Medvedovskaya A. S. Antipova I. Z. Zavodnova A. A. Semenova G. R. Arakelyan Yu. E. Ryabukhina O. A. Kolomeytsev A. D. Shirin E. A. Osmanov A. V. Misyurin |
| author_sort | A. A. Solodovnik |
| collection | DOAJ |
| description | Objective: to study the prognostic significance of the expression of cancer-testis (CT) genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in patients with multiple myeloma (MM) and their influence on overall survival and relapse rate. To determine their effect on suсh clinical parameters as levels of lactate dehydrogenase, leucocytes, hemoglobin, calcium, albumen, creatinine, beta-2-microglobulin.Materials and methods. Real-time polymerase chain reaction was performed on complementary DNA obtained from bone marrow of 77 patients with MM. The statistical analysis was performed using the Statistica 10.0 software package. To estimate prognostic values of the CT gene expression data were analyzed by the Kaplan – Meier method.Results. The study was conducted to determine the level of expression of CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in a group of patients with MM. The group included primary and receiving cancer treatment in MM patients. According to the log-rank criterion expression of any of the CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 exerts a significant influence on overall survival and progression-free survival/relapse. It was also determined that providing expression of some CT genes, the levels of creatinine, calcium, beta-2-microglobulin were much higher to compare with patients without expression. |
| format | Article |
| id | doaj-art-b0aa8abe11aa425e8a24ca45472d22ad |
| institution | Kabale University |
| issn | 2313-805X 2413-3787 |
| language | Russian |
| publishDate | 2018-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Успехи молекулярной онкологии |
| spelling | doaj-art-b0aa8abe11aa425e8a24ca45472d22ad2025-08-20T04:00:14ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872018-07-0152627010.17650/2313-805X-2018-5-2-62-70124EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATEA. A. Solodovnik0H. S. Mkrtchyan1V. A. Misyurin2V. V. Tikhonova3Yu. P. Finashutina4N. N. Kasatkina5O. N. Solopova6O. M. Votyakova7O. Yu. Yakimovich8O. M. Volodina9M. Yu. Kichigina10E. G. Medvedovskaya11A. S. Antipova12I. Z. Zavodnova13A. A. Semenova14G. R. Arakelyan15Yu. E. Ryabukhina16O. A. Kolomeytsev17A. D. Shirin18E. A. Osmanov19A. V. Misyurin20N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaGeneTechnologyN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; GeneTechnologyObjective: to study the prognostic significance of the expression of cancer-testis (CT) genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in patients with multiple myeloma (MM) and their influence on overall survival and relapse rate. To determine their effect on suсh clinical parameters as levels of lactate dehydrogenase, leucocytes, hemoglobin, calcium, albumen, creatinine, beta-2-microglobulin.Materials and methods. Real-time polymerase chain reaction was performed on complementary DNA obtained from bone marrow of 77 patients with MM. The statistical analysis was performed using the Statistica 10.0 software package. To estimate prognostic values of the CT gene expression data were analyzed by the Kaplan – Meier method.Results. The study was conducted to determine the level of expression of CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in a group of patients with MM. The group included primary and receiving cancer treatment in MM patients. According to the log-rank criterion expression of any of the CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 exerts a significant influence on overall survival and progression-free survival/relapse. It was also determined that providing expression of some CT genes, the levels of creatinine, calcium, beta-2-microglobulin were much higher to compare with patients without expression.https://umo.abvpress.ru/jour/article/view/149cancer-testis genesmultiple myelomaoverall survivalprogression-free survival |
| spellingShingle | A. A. Solodovnik H. S. Mkrtchyan V. A. Misyurin V. V. Tikhonova Yu. P. Finashutina N. N. Kasatkina O. N. Solopova O. M. Votyakova O. Yu. Yakimovich O. M. Volodina M. Yu. Kichigina E. G. Medvedovskaya A. S. Antipova I. Z. Zavodnova A. A. Semenova G. R. Arakelyan Yu. E. Ryabukhina O. A. Kolomeytsev A. D. Shirin E. A. Osmanov A. V. Misyurin EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE Успехи молекулярной онкологии cancer-testis genes multiple myeloma overall survival progression-free survival |
| title | EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE |
| title_full | EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE |
| title_fullStr | EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE |
| title_full_unstemmed | EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE |
| title_short | EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE |
| title_sort | expression of cancer testis genes prame ny eso1 gage1 mage a3 mage a6 mage a12 ssx1 sllp1 pasd1 in patients with multiple myeloma their influence on overall survival and relapse rate |
| topic | cancer-testis genes multiple myeloma overall survival progression-free survival |
| url | https://umo.abvpress.ru/jour/article/view/149 |
| work_keys_str_mv | AT aasolodovnik expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT hsmkrtchyan expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT vamisyurin expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT vvtikhonova expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT yupfinashutina expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT nnkasatkina expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT onsolopova expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT omvotyakova expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT oyuyakimovich expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT omvolodina expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT myukichigina expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT egmedvedovskaya expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT asantipova expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT izzavodnova expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT aasemenova expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT grarakelyan expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT yueryabukhina expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT oakolomeytsev expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT adshirin expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT eaosmanov expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate AT avmisyurin expressionofcancertestisgenespramenyeso1gage1magea3magea6magea12ssx1sllp1pasd1inpatientswithmultiplemyelomatheirinfluenceonoverallsurvivalandrelapserate |